Introduction
Preexisting medical comorbidity is of paramount importance in prostate cancer (PCa) treatment decision making. A selection bias exists among cancer specialists for preferring radiation therapy (RT) for patients with significant comorbid illness who are felt not to be candidates for surgery [1, 2] . In addition to influencing treatment choice, medical comorbidity influences mortality after the diagnosis of localized PCa [3, 4] directly through competing causes of death or indirectly by exacerbating underlying disease states [5] . Several groups have reported that underlying medical comorbidity can influence overall mortality (OM) after PCa treatment [6] [7] [8] [9] .
In the absence of randomization, this imbalance of medical comorbidity makes valid comparisons among treatment options difficult. Several comparisons of PCa treatment options have either ignored medical comorbidity because the information was not collected [10] or have attempted to control for measured comorbidity using statistical methods [11] [12] [13] [14] [15] . However, concerns remain that unmeasured factors could still bias results.
Statistically adjusting for comorbidity in observational studies assumes that comorbidity severity is accurately assessed and that measurement error does not result in incomplete statistical adjustment. Experts in the methodology of comparative effectiveness literature have recommended restriction analysis as an alternative to statistical adjustment to minimize the effect of confounding bias [16] . For this reason, we sought to compare mortality among treatments for men with no medical comorbidity. Our objective was to evaluate for any differences in mortalityeither PCa mortality (PCM) or OM in patients treated in the prostate-specific antigen (PSA) era with radical prostatectomy (RP), external-beam RT (EBRT), or brachytherapy (BT).
2.
Patients and methods 
Results
In the cohort of men without measured medical comorbidity, treatment groups differed with respect to age, race, PSA, clinical stage, biopsy Gleason grade, and D'Amico risk group (Table 2) . Median follow-up after treatment was 7.2 yr, while 2397 of 6692 men (35.8%) had evaluation to either death or follow-up for >10 yr. Mortality occurred in 664 men (9.9%), which was classified as PCM in 123 men and other-cause mortality in 541 men. By the KaplanMeier method, the 10-yr PCM was 2.6% and the 10-yr OM was 13.3%. 922 (9) 387 (6) 300 (14) 235 (14) Severe, no. (%)
132 (1) 44 (1) 60 (3) 28 (2) RP = radical prostatectomy; EBRT = external-beam radiation therapy; BT = brachytherapy. * The Adult Comorbidity Evaluation Index-27 comorbidity index groups patients into none, mild, moderate, and severe. Charlson comorbidity index: 0 = none; 1 = mild; 2-3 = moderate; 4 = severe.
Univariate and multivariate Cox proportional hazards models are displayed for PCM in Table 3 . EBRT was associated with an increase in PCM compared with RP (HR: 1.66; 95% confidence interval [CI], 1.05-2.63); for BT there was also an elevated hazard ratio (HR: 1.83) for PCM compared with RP, but it was not statistically significant (95% CI for HR, 0.88-3.82) (Fig. 1) . When covariates for propensity score analysis were included in the analysis of PCM, the relationships on multivariable analysis remained similar, with EBRT associated with an increase in PCM compared with RP (HR: 1.64; 95% CI, 1.05-2.55; p = 0.03) and a similar HR for PCM with BT compared with RP (HR: 1.63; 95% CI, 0.77-3.45).
PCM was additionally evaluated using Fine and Gray competing risks analysis (Table 3) . When using a competing risks model, there was no statistically significant increase in PCM for EBRT compared with RP (HR: 1.55; 95% CI, 0.92-2.60) or for BT compared with RP (HR: 1.66; 95% CI, 0.79-3.46).
Results for OM are shown in Table 4 . In comparison with RP, both EBRT (HR: 1.71; 95% CI, 1.40-2.08) and BT (HR:
1.78; 95% CI, 1.37-2.31) were associated with increased OM (Fig. 2) . When using the propensity adjustment method in the multivariable analysis of OM, the relationships remained similar, with an increase in OM with EBRT (HR: 1.67; 95% CI, 1.37-2.04; p < 0.0001) and with BT (HR: 1.69; 95% CI, 1.30-2.19; p < 0.0001) compared with RP.
Discussion
In an effort to minimize the confounding due to underlying medical comorbidity, we evaluated mortality after PCa treatment in men with no documented medical comorbidity at the time of PCa treatment. In this patient cohort, PCM was infrequent. A Cox proportional hazards statistical analysis identified that EBRT was associated with an increase in PCM compared with RP, even when adjusting for differences in patient demographics and cancer severity. However, the association of EBRT with increased PCM was no longer statistically significant when evaluated with a competing risks model. This association, of similar magnitude with either model, raises speculation that the (7) 346 (27) 17 (2) RP = radical prostatectomy; EBRT = external-beam radiation therapy; BT = brachytherapy; PSA = prostate-specific antigen. 
treatment efficacy of historical RT may have been diminished compared with surgery during the same time period; however, lack of a statistically significant effect does not allow a definitive conclusion. The lack of a difference in PCM with BT may be related to the use of BT in lower-risk patients and avoidance in high-risk patients, as it is known that mortality from low-risk PCa is a relatively infrequent occurrence, to the extent that some low-risk patients may not even warrant active treatment. In addition, the number of patients treated with BT was relatively lower, which is reflected in the wider confidence interval and lower certainty of the findings. With respect to OM, both forms of RT were associated with an increase in OM compared with surgery. The finding of increased OM after RTs could potentially be due to treatment toxicity. Speculative reasons for increased mortality after irradiation include a clinically significant increased rate of secondary malignancy after irradiation [22, 23] or secondary toxicity from androgen-deprivation therapy (ADT), which is used more commonly with irradiation than surgery. However, the link between androgen deprivation and cardiovascular toxicity remains controversial [24, 25] .
The fact that the differences in OM with radiation treatment modalities compared with surgery were more pronounced than in PCM has several possible explanations. PCM during our cohort was relatively low, so the small number of events limits our ability to evaluate the relationship. In addition, cause-of-death data from death records can be unreliable [26] . Therefore, patients whose 0 1 3 ) 3 7 2 -3 7 8 recorded death was from other causes may have in fact died of PCa; however, it is not known if this error would differ based on treatment modality. We attempted to minimize this error by reviewing all available records and not solely depending on death certificate data. Our evaluation relied on retrospective observational data to compare the mortality outcomes of treatment options for localized PCa. The reliance on observational data is necessary because randomized controlled trials are lacking. Other groups have attempted to use observational data to compare treatment outcomes with varying methods to evaluate and control for comorbidity. Adbollah et al. [14] used Surveillance Epidemiology and End Results (SEER) data and concluded that RP provided more favorable survival rates compared with RT with median follow-up of 4.3 yr. However, a limitation of SEER data is the lack of any information on medical comorbidity. Using the SEER cancer registry data linked to Medicare, which allowed attempted statistical adjustment for comorbidity but was limited to patients >65 yr, Abdollah [14] recently reported improved outcomes with surgery compared with irradiation for PCa, as had Liu et al. (median follow-up was not reported) [27] . Another population-based evaluation in a Canadian province, which included attempted statistical control for medical comorbidity, also reported increased mortality after RT compared with surgery [28] .
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Kutikov et al. recently reported on a nomogram using data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) that reported on multivariate analysis that treatment with irradiation was associated with increased risk of PCa and non-PCa death [29] . Previously, Cooperberg et al. had used data from CaPSURE and, after statistically adjusting for Charlson comorbidity, concluded that surgery was associated with a significant and substantial reduction in mortality relative to RT. Cooperberg et al. reported that this finding was unlikely due to unmeasured confounding, as statistical adjustments and sensitivity analysis did not affect the results [15] . Our analysis differed, as we restricted our evaluation to men with no measured comorbidity in an attempt to minimize unmeasured confounding bias. In a two-institution evaluation of high-risk PCa, Boorjian et al. [13] reported that PCM was similar for RP and EBRT (follow-up of 10.2 and 6-7.2 yr, respectively); however, OM was increased after EBRT if patients received ADT. In an effort to minimize confounding, Boorjian et al. also reported that when restricting this analysis to the subset of patients with a Charlson comorbidity index of 0 or 1, this relationship was unchanged. Our analysis differed, as we attempted to include only healthy patients and excluded patients with Charlson comorbidity of 1, which can include myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, connective tissue disorder, ulcer disease, mild liver disease, or diabetes without end organ damage [17] .
A primary concern in any evaluation comparing different treatment options for PCa is the possibility that unmeasured confounding differences exist between men who chose to receive irradiation compared with surgery. The RT group had higher stage, grade, and PSA and was older and more likely to be African American. It is likely that additional unmeasured variables exist between the two groups. We attempted to minimize the potential for confounding by restricting our analysis to men with no measured pretreatment medical comorbidity, which would be a presumptively healthy group, and statistically controlling for differences between treatment groups in age, race, PSA, biopsy Gleason grade, and clinical stage.
This nonrandomized observational evaluation has limitations. While the comorbidity indexes used in our study identified and excluded men with measured pretreatment medical comorbidities, there are other possible unmeasured treatment differences between groups. For instance, morbid obesity (body mass index 38) and hypertension are captured by the ACE-27 comorbidity index; however, these factors are not assessed in the Charlson comorbidity index. A history of smoking, hypercholesterolemia, or socioeconomic status are also not assessed by either comorbidity index and may have differed by treatment group. The possibility also exists that when suggesting treatment modality, clinicians may be able to identify differences in patients that are not accurately assessed by comorbidity indexes. Whether the impact of these unmeasured factors is influential enough to explain our findings remains unknown, and further research will be needed to elucidate whether and how much of a mortality difference exists in healthy patients undergoing treatment of PCa.
We restricted our analysis to men with no measured comorbidity, so the results of our analysis are best applied to that population and not generalized to all men with PCa.
There is debate about who should be treated (with any modality) for PCa. Given that patients with no comorbidity have longer life expectancies, our analysis addresses the population most likely to benefit from treatment and therefore of greatest interest. In our study, median followup was >7 yr; further follow-up is necessary, however, as PCM can occur years after treatment.
The RT given was consistent with the standard of care at the time, but dose escalation has occurred over time, and the effect on mortality of contemporary doses of RT cannot be evaluated in this study. The use of ADT could not be controlled for in the statistical model because surgical patients did not receive ADT at the time of treatment. The administration of ADT in the context of EBRT was predicated on the standard of care at the time treatment was delivered [12] . More recently, the adoption of ADT in men with unfavorable-risk PCa has been reported to improve survival in patients treated with EBRT [30, 31] and potentially could affect results in a more contemporary cohort. In addition, detailed information on the receipt of salvage therapies was not available for the entire cohort.
While our results suggested a survival benefit for prostatectomy in men with no measured comorbidity, patient choice remains important, as treatment choice incorporates not only available data on cure rates but also concerns about the adverse effects of primary treatment. Other factors such as quality of life, continence, and erectile function also affect treatment decisions [32, 33] and were not evaluated in this report. Finally, our study did not include an active surveillance cohort, and active surveillance is an option for low-risk PCa [34] .
Conclusions
In a large multicenter series of men without recorded comorbidity, both forms of RT were associated with an increase in OM compared with surgery. These findings may result from differences in cancer control, mortality related to primary or salvage therapy, or an imbalance of confounders.
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